{"id":2355,"date":"2025-01-08T17:41:32","date_gmt":"2025-01-08T14:41:32","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2355"},"modified":"2025-03-07T15:26:36","modified_gmt":"2025-03-07T12:26:36","slug":"avidity-biosciences-prepares-for-three-rare-muscle-disease-programs-2025-bla-submission-and-commercialization","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/avidity-biosciences-prepares-for-three-rare-muscle-disease-programs-2025-bla-submission-and-commercialization\/","title":{"rendered":"Avidity Biosciences se pr\u00e9pare \u00e0 la soumission et \u00e0 la commercialisation de trois programmes de maladies musculaires rares pour BLA 2025"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Avidity Biosciences, Inc., une soci\u00e9t\u00e9 biopharmaceutique d\u00e9di\u00e9e au d\u00e9veloppement d&#039;une nouvelle classe de traitements \u00e0 base d&#039;ARN connue sous le nom de conjugu\u00e9s d&#039;oligonucl\u00e9otides d&#039;anticorps (AOCsTM), a annonc\u00e9 aujourd&#039;hui ses avanc\u00e9es et ses plans pour une ann\u00e9e de changement en 2025.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ces \u00e9tapes importantes attendues comprennent l&#039;ach\u00e8vement de trois programmes potentiellement enregistrables, la soumission d&#039;une demande de licence de produit biologique (BLA) pour le delpacibart zotadirsen (del-zota) pour les personnes atteintes de mutations de la dystrophie musculaire de Duchenne sensibles au saut d&#039;exon 44 (DMD44), la pr\u00e9paration de plusieurs lancements de produits dans le domaine de la DMD44, de la dystrophie myotonique de type 1 (DM1) et de la dystrophie musculaire facio-scapulo-hum\u00e9rale (FSHD), et l&#039;\u00e9tablissement d&#039;une entreprise internationale enti\u00e8rement int\u00e9gr\u00e9e pour soutenir un pipeline AOC en expansion dans le domaine de la cardiologie de pr\u00e9cision et des maladies neuromusculaires.<\/p>","protected":false},"excerpt":{"rendered":"<p>A biopharmaceutical firm dedicated to developing a novel class of RNA treatments known as Antibody Oligonucleotide Conjugates (AOCsTM), Avidity Biosciences, Inc., today reported its advancements and plans for a game-changing year in 2025. These significant expected milestones include completing three potentially registrational programs, submitting a Biologics License Application (BLA) for delpacibart zotadirsen (del-zota) for individuals [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2357,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[126,128,130,129,66,77],"class_list":["post-2355","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-avidity-biosciences","tag-bla","tag-dm1","tag-dmd44","tag-duchenne-muscular-dystrophy","tag-exon-skipping"],"subtitle":"Avidity Biosciences, Inc., une soci\u00e9t\u00e9 biopharmaceutique produisant des th\u00e9rapies \u00e0 base d'ARN conjugu\u00e9s d'oligonucl\u00e9otides d'anticorps (AOC), a annonc\u00e9 ses progr\u00e8s et ses objectifs pour une ann\u00e9e 2025 transformatrice.","_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/2355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=2355"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/2355\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/2357"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=2355"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=2355"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=2355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}